Following in the footsteps of the other review programs at the US Food and Drug Administration's (FDA) Office of Pharmaceutical Science, the Office of Biotechnology Products (OBP) is currently in the ...
There are three technical enablers “that repeatedly separate successful [AI] deployments from stalled pilots: trustworthy data pipelines, fit-for-purpose model selection, and lifestyle governance,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results